Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178895 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL25143 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL2182769 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL17746959 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178762 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178760 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178759 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178761 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178758 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C | |
| SCHEMBL178892 | 1.00 | KMT2A (1.00) | KMT2AHTTEPHX2CASP3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118027136-A | Paper-assisted polypeptide integrated green synthesis method | 北京中医药大学 | 2024-05-14 | — | — | CN | disclosed |
| EP-4168121-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115702026-A | Macrocyclic compounds and methods of use thereof | 基因泰克公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-4100042-A1 | REVERSE AMIDE-LINKED MELANOCORTIN RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-115279390-A | Reverse amide linked melanotropin receptor specific cyclic peptides | 帕拉丁科技公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2021262731-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| EP-1226167-A1 | MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY | Akzo Nobel N.V. (NL) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001029081-A1 | MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY | AKZO NOBEL N.V. (NL) | 2001-04-26 | — | — | WO | disclosed |
| EP-0710244-A1 | IMMUNOREACTIVE REAGENTS EMPLOYING MONOAMINE OXIDASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-08 | — | — | EP | disclosed |
| WO-1994029333-A1 | IMMUNOREACTIVE REAGENTS EMPLOYING MONOAMINE OXIDASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885HTT 613/4885EPHX2 579/4885 |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | KMT2A 2834/4885HTT 613/4885EPHX2 579/4885 |
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | KMT2A 1046/4885HTT 4854/4885EPHX2 3515/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | KMT2A 735/4885HTT 4850/4885EPHX2 3415/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | KMT2A 2834/4885HTT 613/4885EPHX2 579/4885 |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | MC1R, NPY1R, MC3R | KMT2A 2310/4885HTT 1040/4885EPHX2 3034/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | KMT2A 918/4885HTT 4846/4885EPHX2 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.